{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:43:28Z","timestamp":1791283408042,"version":"4.1.0"},"reference-count":46,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Pneumococcal infection strongly contributes to morbidity and mortality in Spain. A total of 253,899 hospitalizations related to pneumococcal infection occurred from 2016 to 2020. Fifty-eight percent were men, the mean age was 67 years old, and the average length of hospitalization was 12.72 days. The annual hospitalization rate was 10.84 hospitalizations per 10,000 population, increasing significantly with age, reaching 65.75 per 10,000 population in those aged &gt;85 years. The hospitalization rates for pneumococcal pneumonia, sepsis, and meningitis were 2.91, 0.12, and 0.08 hospitalizations per 10,000, respectively, and reached the highest value in those aged &gt;85 for pneumococcal pneumonia and sepsis, with 22.29 and 0.71 hospitalizations per 10,000, respectively, and in children up to 1 year old for pneumococcal meningitis, with 0.33 hospitalizations per 10,000. The total number of deaths during the study period was 35,716, with a case-fatality rate of 14.07%. For pneumococcal pneumonia, sepsis, and meningitis, the case-fatality rates were 8.47%, 23.71%, and 9.99%, respectively. The case-fatality rate increased with age and did not vary by sex. The annual cost of these hospitalizations was more than EUR 359 million. There is therefore a high burden of disease and mortality caused by pneumococcal infection in our country, especially in elderly individuals.<\/jats:p>","DOI":"10.3390\/antibiotics12010172","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T02:29:55Z","timestamp":1673836195000},"page":"172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Burden of Hospitalizations Related to Pneumococcal Infection in Spain (2016\u20132020)"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5229-3832","authenticated-orcid":false,"given":"Ruth","family":"Gil-Prieto","sequence":"first","affiliation":[{"name":"Preventive Medicine and Public Health, Rey Juan Carlos University, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Allouch","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Public Health, Rey Juan Carlos University, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Jimeno","sequence":"additional","affiliation":[{"name":"Primary Care Health Center Isla de Oza, Vaccine Responsible of SEMG, 28035 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Hern\u00e1ndez-Barrera","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Public Health, Rey Juan Carlos University, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-6347","authenticated-orcid":false,"given":"Raquel","family":"Arguedas-Sanz","sequence":"additional","affiliation":[{"name":"Department of Business Economics and Accounting, Universidad Nacional de Educaci\u00f3n a Distancia UNED, 28004 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-7101","authenticated-orcid":false,"given":"\u00c1ngel","family":"Gil-de-Miguel","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Public Health, Rey Juan Carlos University, 28922 Madrid, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"ref_1","unstructured":"Collaborators GBDLRI (2018). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis., 18, 1191\u20131210."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s15010-015-0801-y","article-title":"Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults","volume":"43","author":"Gomez","year":"2015","journal-title":"Infection"},{"key":"ref_3","first-page":"84","article-title":"The role of immunosenescence in the development of age-related diseases","volume":"68","author":"Dupuis","year":"2016","journal-title":"Rev. De Investig. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","article-title":"Etiology of community-acquired pneumonia: Increased microbiological yield with new diagnostic methods","volume":"50","author":"Johansson","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","first-page":"509","article-title":"Direct medical costs of four vaccine-preventable infectious diseases in older adults in spain","volume":"6","author":"Callejo","year":"2022","journal-title":"Pharm. Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/03007995.2021.1876007","article-title":"Hospital incidence, in-hospital mortality and medical costs of pneumococcal disease in spain (2008\u20132017): A retrospective multicentre study","volume":"37","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_7","first-page":"411","article-title":"Vacunaci\u00f3n frente a la neumon\u00eda adquirida en la comunidad del adulto. actualizaci\u00f3n 2021 del posicionamiento del grupo de neumoexpertos en prevenci\u00f3n","volume":"47","author":"Redondo","year":"2021","journal-title":"Semer. Med. De Fam."},{"key":"ref_8","unstructured":"(2022, November 14). Vacunas Frente a Neumococo. Available online: https:\/\/neumoexpertos.org\/2021\/05\/26\/recomendaciones-de-vacunacion-antineumococica-en-los-adultos-de-riesgo-o-por-edad-en-las-diferentes-comunidades-autonomas-de-espana\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.vaccine.2010.11.025","article-title":"The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003\u20132007)","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/21645515.2017.1264796","article-title":"Hospitalizations for pneumonia, invasive diseases and otitis in Tuscany (Italy), 2002\u20132014: Which was the impact of universal pneumococcal pediatric vaccination?","volume":"13","author":"Boccalini","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/1403494815581695","article-title":"Clinical burden of pneumonia, meningitis and septicemia in Norway 2 years after 7-valent pneumococcal conjugate vaccine introduction","volume":"43","author":"Munson","year":"2015","journal-title":"Scand. J. Public Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1183\/09031936.00216711","article-title":"Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009","volume":"41","author":"Froes","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1080\/21645515.2021.1923348","article-title":"Burden of pneumococcal disease among adults in southern europe (spain, portugal, italy, and greece): A systematic review and meta-analysis","volume":"17","author":"Montuori","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2018.02.007","article-title":"Burden of pneumococcal community-acquired pneumonia in adults across europe: A literature review","volume":"137","author":"Torres","year":"2018","journal-title":"Respir. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/INF.0000000000003095","article-title":"Stable Incidence of Invasive Pneumococcal Disease in Children in Northern France from 2014 Through 2018","volume":"40","author":"Coronas","year":"2021","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1093\/cid\/ciab1014","article-title":"Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study","volume":"75","author":"Danino","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jpids\/piac056","article-title":"Decrease in Pediatric Invasive Pneumococcal Disease During the COVID-19 Pandemic","volume":"11","author":"Kaplan","year":"2022","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","article-title":"Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: A prospective analysis of surveillance data","volume":"3","author":"Brueggemann","year":"2021","journal-title":"Lancet Digit. Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1016\/S2666-5247(21)00090-2","article-title":"Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: A multicentre, prospective cohort study","volume":"2","author":"Russell","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_20","first-page":"1900","article-title":"Risk of hospitalization due to pneumococcal disease in adults in spain. the CORIENNE study","volume":"12","author":"Walter","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Barbieri, E., Porcu, G., Petigara, T., Senese, F., Prandi, G.M., Scamarcia, A., Cantarutti, L., Cantarutti, A., and Giaquinto, C. (2022). The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy. Children, 9.","DOI":"10.3390\/children9091347"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268822000607","article-title":"Estimation of the incidence of hospitalization for non-invasive pneumococcal pneumonia in the Norwegian population aged 50 years and older","volume":"150","author":"Lyngstad","year":"2022","journal-title":"Epidemiol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14760584.2019.1582337","article-title":"Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States","volume":"18","author":"Wiese","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101271","DOI":"10.1016\/j.eclinm.2022.101271","article-title":"Non-invasive pneumococcal pneumonia due to vaccine serotypes: A systematic review and meta-analysis","volume":"44","author":"Lansbury","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.vaccine.2019.04.087","article-title":"Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia","volume":"37","author":"Isturiz","year":"2019","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Astengo, M., Paganino, C., Amicizia, D., Sticchi, L., Orsi, A., Icardi, G., Piazza, M.F., Mohanty, S., Senese, F., and Prandi, G.M. (2022). Incidence of Hospitalisation and Emergency Department Visits for Pneumococcal Disease in Children, Adolescents, and Adults in Liguria, Italy: A Retrospective Analysis from 2012\u20132018. Vaccines, 10.","DOI":"10.3390\/vaccines10091375"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10096-021-04386-0","article-title":"The impact of pneumococcal conjugate vaccine on the prevalence and severity of hospitalizations for pneumonia in children","volume":"41","author":"Eichler","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1016\/j.vaccine.2022.07.041","article-title":"Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020","volume":"40","author":"Maeda","year":"2022","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1473-3099(20)30165-1","article-title":"Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: An interrupted time-series analysis of data from a 17-year national prospective surveillance study","volume":"21","author":"Ouldali","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e221111","DOI":"10.1001\/jamanetworkopen.2022.1111","article-title":"Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine","volume":"5","author":"Hsiao","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1016\/j.vaccine.2022.07.035","article-title":"Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans","volume":"40","author":"Narsingam","year":"2022","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/infdis\/jiab474","article-title":"Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study","volume":"225","author":"Heo","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40265-022-01733-z","article-title":"20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e3778","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide trends of invasive pneumococcal disease in spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","volume":"73","author":"Domenech","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","article-title":"Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: A systematic review and meta-analysis","volume":"5","author":"Shiri","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/j.vaccine.2022.06.024","article-title":"Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States","volume":"40","author":"Huang","year":"2022","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/14760584.2022.2104250","article-title":"Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England","volume":"21","author":"Mugwagwa","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_38","unstructured":"(2022, November 16). Considerations for Age-Based and Risk-Based Use of PCV15 and PCV20 among U.S. Adults and Proposed Policy Options Miwako Kobayashi, MD, MPH ACIP Meeting. National Center for Immunization & Respiratory Diseases CDC, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-10-20-21\/02-Pneumococcal-Kobayashi-508.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1016\/j.vaccine.2018.10.015","article-title":"Pneumococcal vaccination patterns among persons aged 65 years or older in the United States: A retrospective database analysis","volume":"36","author":"Yang","year":"2018","journal-title":"Vaccine"},{"key":"ref_40","unstructured":"Gencat (2022, November 16). Calendari de Vacunacions Sistem\u00e0tiques 2022. Available online: https:\/\/canalsalut.gencat.cat\/web\/.content\/_A-Z\/V\/vacunacions\/documents\/calendari_vacunacions.pdf."},{"key":"ref_41","unstructured":"Regi\u00f3n de Murcia (2022, November 16). Vacunaci\u00f3n Estacional Frente a Infecciones Respiratorias (Gripe, Neumococo y Covid-19) en Personas a Partir de 60 A\u00f1os y Grupos de Riesgo de Cualquier Edad. Available online: https:\/\/www.murciasalud.es\/recursos\/ficheros\/508761-Protocolo_Campana_de_gripe_y_neumo_2022-23_v4.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.54886\/scire.v24i1.4506","article-title":"Del MBDS al big data en salud: Un sistema de informaci\u00f3n hospitalaria para el siglo XXI","volume":"24","author":"Cuenca","year":"2018","journal-title":"Scire"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/jamiaopen\/ooz066","article-title":"A narrative review of the impact of the transition to ICD-10 and ICD-10-CM\/PCS","volume":"3","author":"Kusnoor","year":"2020","journal-title":"JAMIA Open"},{"key":"ref_44","first-page":"651","article-title":"Evaluaci\u00f3n de calidad a partir del conjunto m\u00ednimo de datos b\u00e1sicos al alta hospitalaria","volume":"29","author":"Librero","year":"1999","journal-title":"Rev. Neurol."},{"key":"ref_45","unstructured":"Ministerio de Sanidad (2022, November 14). Registro de Atenci\u00f3n Especializada (RAE-CMBD), Available online: https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/N\/rae-cmbd\/rae-cmbd."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10729-006-9040-1","article-title":"Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries","volume":"9","author":"Stargardt","year":"2006","journal-title":"Health Care Manag. Sci."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:55Z","timestamp":1760119555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["antibiotics12010172"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12010172","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]}}}